Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1998 1
2000 2
2002 2
2003 2
2006 1
2007 2
2008 4
2009 5
2010 2
2011 3
2012 2
2013 2
2014 1
2015 1
2016 2
2017 2
2018 7
2019 7
2020 8
2021 5
2022 6
2023 7
2024 5
2025 11
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean homa pm (1 results)?
The More Recent History of Hemophilia Treatment.
Franchini M, Mannucci PM. Franchini M, et al. Semin Thromb Hemost. 2022 Nov;48(8):904-910. doi: 10.1055/s-0042-1756188. Epub 2022 Sep 15. Semin Thromb Hemost. 2022. PMID: 36108649 Free article. Review.
Another section is focused on the current state of gene therapy, which is a promising definitive cure for severe hemophilia A and B....
Another section is focused on the current state of gene therapy, which is a promising definitive cure for severe hemophilia A …
Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group.
Pfrepper C, Klamroth R, Oldenburg J, Holstein K, Eichler H, Hart C, Moehnle P, Schilling K, Trautmann-Grill K, Alrifai M, Ay C, Miesbach W, Knoebl P, Tiede A. Pfrepper C, et al. Hamostaseologie. 2024 Dec;44(6):466-471. doi: 10.1055/a-2197-9738. Epub 2023 Dec 4. Hamostaseologie. 2024. PMID: 38049124 Free article.
BACKGROUND: Acquired hemophilia A (AHA) is a severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). ...
BACKGROUND: Acquired hemophilia A (AHA) is a severe bleeding disorder caused by autoantibodies against coagulation factor VII …
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Négrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Bernardi RJ, Jiménez-Yuste V, Beckermann BM, Schmitt C, Ventriglia G, Windyga J, d'Oiron R, Moorehead P, Koparkar S, Teodoro V, Shapiro AD, Oldenburg J, Hermans C. Négrier C, et al. Lancet Haematol. 2023 Mar;10(3):e168-e177. doi: 10.1016/S2352-3026(22)00377-5. Epub 2023 Jan 27. Lancet Haematol. 2023. PMID: 36716761 Clinical Trial.
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.
Tiede A, Hart C, Knöbl P, Greil R, Oldenburg J, Sachs UJ, Miesbach W, Pfrepper C, Trautmann-Grill K, Holstein K, Pilch J, Möhnle P, Schindler C, Weigt C, Schipp D, May M, Dobbelstein C, Pelzer FJ, Werwitzke S, Klamroth R. Tiede A, et al. Lancet Haematol. 2023 Nov;10(11):e913-e921. doi: 10.1016/S2352-3026(23)00280-6. Epub 2023 Oct 16. Lancet Haematol. 2023. PMID: 37858328 Clinical Trial.
Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A.
Schimansky IM, Dobbelstein C, Klamroth R, Hart C, Sachs UJ, Greil R, Knöbl P, Oldenburg J, Miesbach W, Pfrepper C, Trautmann-Grill K, Möhnle P, Holstein K, Eichler H, Werwitzke S, Tiede A. Schimansky IM, et al. Blood Adv. 2025 Nov 25;9(22):5853-5860. doi: 10.1182/bloodadvances.2025017144. Blood Adv. 2025. PMID: 40795229 Free PMC article. Clinical Trial.
Acquired hemophilia A (AHA) is a severe bleeding disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII). ...
Acquired hemophilia A (AHA) is a severe bleeding disorder caused by neutralizing autoantibodies against coagulation factor VII …
No correlation between thrombin generation and emicizumab levels: implications for monitoring emicizumab therapy.
van der Zwet K, Roest M, Huskens D, Schutgens REG, van Vulpen LFD, Fischer K, Urbanus RT. van der Zwet K, et al. Res Pract Thromb Haemost. 2024 Dec 17;9(1):102658. doi: 10.1016/j.rpth.2024.102658. eCollection 2025 Jan. Res Pract Thromb Haemost. 2024. PMID: 39850577 Free PMC article.
BACKGROUND: Emicizumab, a bispecific antibody that mimics factor (F)VIII, has significantly improved hemophilia A management. Although emicizumab levels can be measured, tools for estimating the hemostatic efficacy of emicizumab are lacking. ...TG was measured using …
BACKGROUND: Emicizumab, a bispecific antibody that mimics factor (F)VIII, has significantly improved hemophilia A management. …
Hemophilia treatment innovation: 50 years of progress and more to come.
Mannucci PM. Mannucci PM. J Thromb Haemost. 2023 Mar;21(3):403-412. doi: 10.1016/j.jtha.2022.12.029. J Thromb Haemost. 2023. PMID: 36858789 Free article. Review.
Subsequently, the unmet needs pertaining to therapeutic adherence and thus to prophylaxis effectiveness led to the availability of factor VIII and IX products with an extended plasma half-life as well as to emicizumab, the first nonfactor medicine for subcutaneous administration …
Subsequently, the unmet needs pertaining to therapeutic adherence and thus to prophylaxis effectiveness led to the availability of factor VI …
Emicizumab, the factor VIII mimetic bispecific monoclonal antibody: effects on thrombin generation and thromboelastometry.
Tripodi A, Clerici M, Scalambrino E, Arcudi S, Gualtierotti R, Novembrino C, Peyvandi F. Tripodi A, et al. Res Pract Thromb Haemost. 2025 Oct 27;9(8):103237. doi: 10.1016/j.rpth.2025.103237. eCollection 2025 Nov. Res Pract Thromb Haemost. 2025. PMID: 41322968 Free PMC article.
BACKGROUND: Emicizumab is used for prophylaxis of patients with hemophilia A. Because it is used at a fixed dose that is not based on laboratory testing, evaluation of its activity is occasionally needed. ...The best TGA condition in terms of reagent composition was …
BACKGROUND: Emicizumab is used for prophylaxis of patients with hemophilia A. Because it is used at a fixed dose that is not b …
Paper-based immunocapture for targeted protein analysis.
Skjærvø Ø, Solbakk EJ, Halvorsen TG, Reubsaet L. Skjærvø Ø, et al. Talanta. 2019 Apr 1;195:764-770. doi: 10.1016/j.talanta.2018.12.013. Epub 2018 Dec 7. Talanta. 2019. PMID: 30625614
A novel sampling concept for mass spectrometric bottom-up targeted protein analysis is here demonstrated with polymeric sampling spots integrated with instant immunocapture for analysis of dried matrix spots. The polymers 2-hydroxyethyl methacrylate-co-2-vinyl-4,4-d …
A novel sampling concept for mass spectrometric bottom-up targeted protein analysis is here demonstrated with polymeric sampling spots integ …
84 results